Abstract: DNA double-strand breaks (DSBs) are among the most deleterious types of DNA damage, typically induced by ionizing radiation (IR) and specific chemotherapeutic agents. The DNA-dependent protein kinase (DNA-PK) plays a critical role in repairing these breaks through the non-homologous end joining (NHEJ) pathway. NU7441 (also known as KU-57788) is a highly potent and selective small-molecule inhibitor of the DNA-PK catalytic subunit (DNA-PKcs). Developed through the structural optimization of earlier phosphatidylinositol 3-kinase (PI3K) inhibitors, NU7441 exhibits remarkable selectivity for DNA-PK over other PI3K-related kinases (PIKKs). By blocking DNA-PK activity, NU7441 effectively impairs DSB repair, thereby profoundly sensitizing cancer cells to radiotherapy and chemotherapy both in vitro and in vivo. Although its clinical translation has been limited by poor water solubility, NU7441 remains a vital preclinical tool compound that has paved the way for the development of next-generation DNA-PK inhibitors currently in clinical trials.
1. Introduction
Ionizing radiation (IR) and a subset of anticancer drugs exert their therapeutic effects primarily by inducing DNA damage, with DNA double-strand breaks (DSBs) being the most lethal form. In eukaryotic cells, DSBs are predominantly repaired via two main pathways: homologous recombination (HR) and non-homologous end joining (NHEJ) [1]. The DNA-dependent protein kinase (DNA-PK) is a massive molecular sensor essential for the NHEJ pathway. It is composed of a catalytic subunit (DNA-PKcs) and a Ku heterodimer (Ku70/Ku80) that binds to the ends of double-stranded DNA [1]. Because cells deficient in DNA-PKcs exhibit hypersensitivity to IR and DNA-damaging agents, targeting DNA-PK has emerged as a promising strategy for cancer radiosensitization and chemosensitization [1]. NU7441 was developed as a highly potent and selective DNA-PK inhibitor based on the structural similarities between DNA-PK and phosphatidylinositol 3-kinases (PI3Ks), serving as a critical agent for enhancing the efficacy of cancer therapies [1].
2. Pharmacological Activity
NU7441 demonstrates exceptional pharmacological potency and selectivity against DNA-PK. In vitro assays reveal that NU7441 inhibits DNA-PK with an IC50 of 14 nM [1]. Importantly, it exhibits high selectivity over other PI3K-related kinases (PIKKs) and PI3Ks; its IC50 values for Ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) kinases are greater than 100,000 nM, while its IC50 for mTOR is 1,700 nM and for PI3Kα is 5,000 nM [1].
In cellular models (in cellulo), NU7441 at a concentration of 0.5 µM successfully sensitizes cultured cancer cells to ionizing radiation and the chemotherapeutic drug etoposide in a DNA-PKcs-dependent manner [1]. In vivo studies further validate its therapeutic potential; intraperitoneal (i.p.) administration of NU7441 at doses of 10–25 mg/kg significantly potentiates tumor growth suppression when combined with radiation or etoposide [1].
3. Molecular Mechanism of Action
The primary mechanism of action of NU7441 involves the direct and selective inhibition of the DNA-PK catalytic subunit (DNA-PKcs). Upon the induction of DSBs by radiation or chemotherapeutic agents, the Ku70/Ku80 heterodimer recognizes and binds to the broken DNA ends, subsequently recruiting and activating DNA-PKcs to initiate the NHEJ repair cascade [1]. By binding to the ATP-binding pocket of DNA-PKcs, NU7441 blocks the kinase activity that is absolutely required for the NHEJ process. The failure to repair these lethal DNA lesions leads to augmented cellular sensitivity to DNA-damaging treatments, ultimately driving the cancer cells toward apoptosis or mitotic catastrophe [1].
4. Structure-Activity Relationship (SAR)
NU7441 (chemically known as 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one) was discovered through the screening and structural modification of chromenone libraries derived from the earlier, less selective PI3K inhibitor LY294002 [1]. The structural evolution from LY294002 to NU7026, and ultimately to NU7441, highlights the importance of specific functional groups for target affinity.
Recent cryo-electron microscopy (cryo-EM) studies have elucidated the precise binding mode of NU7441 within DNA-PKcs. The molecule features multiple critical interactions: the chromen and morpholine groups insert deeply into a hydrophobic pocket formed by the amino acid residues Leu3751, Tyr3791, Ile3803, Leu3986, and Ile3940 [1]. Concurrently, the dibenzothiophene group inserts into an adjacent hydrophobic pocket formed by Met3729, Pro3735, and Leu3751 [1]. These dual, deep hydrophobic insertions explain why NU7441 possesses significantly higher affinity and selectivity for DNA-PKcs compared to earlier inhibitors like wortmannin or LY294002 [1].
5. Current Limitations
Despite its high potency and selectivity, the clinical translation of NU7441 has been hindered by its physicochemical properties, most notably its poor water solubility [1]. This limitation restricts its formulation and oral bioavailability for human clinical trials. Consequently, NU7441 has primarily been utilized as an extensive preclinical tool compound for functional studies of DNA-PK rather than progressing into clinical development [1]. To overcome this barrier, researchers have had to synthesize derivatives, such as KU-0060648, which was specifically modified from the NU7441 scaffold to increase water solubility [1].
6. Future Perspectives
While NU7441 itself may not reach the clinic, its development marks a pivotal milestone in the evolution of DNA-PK inhibitors. It has served as a foundational molecule that proved the concept of DNA-PK inhibition for radio- and chemosensitization. The structural insights gained from NU7441's interaction with DNA-PKcs are currently guiding structure-based drug design [1]. This has directly inspired the creation of next-generation derivatives like NU5455 (which shows oral bioavailability and high selectivity) and LTURM34 [1]. Furthermore, the paradigm established by NU7441 has paved the way for recently developed, clinically viable DNA-PK inhibitors such as M3814 (peposertib) and AZD7648, which are currently undergoing Phase 1 and 2 clinical trials in combination with radiotherapy and chemotherapy [1].
